

Bhaven N. Sampat

Johns Hopkins University | Hopkins Bloomberg Center | Washington, DC 20001

sampat@jhu.edu | bhavensampat.github.io

Curriculum Vitae — April 2026

ACADEMIC APPOINTMENTS

Johns Hopkins University

- School of Government and Policy (SGP) and Carey Business School (CBS), 2025-Present

Arizona State University

- Faculty Affiliate, Consortium for Science, Policy, and Outcomes , 2023-Present
- Professor, School of Public Affairs and School for the Future of Innovation in Society, 2023-2025

Columbia University

- Professor, Department of Health Policy and Management (HPM), Mailman School of Public Health, 2021-2023
- Associate Professor, Department of Health Policy and Management (HPM), Mailman School of Public Health, 2012-2021.
- Assistant Professor, Department of Health Policy and Management (HPM), Mailman School of Public Health, 2005 - 2012

New York University

- Distinguished Scholar in Residence, Engelberg Center on Law and Innovation Policy, NYU School of Law, 2015-2016.
- Visiting Professor, Robert F. Wagner School of Public Service, 2015-2016.

University of Michigan

- Robert Wood Johnson Foundation Scholar in Health Policy Research, Department of Health Management and Policy, School of Public Health, 2003-2005.

Georgia Institute of Technology,

- Assistant Professor, School of Public Policy, 2001-2003.

OTHER AFFILIATIONS

Abdul Latif Jameel Poverty Action Lab (J-PAL) Science for Progress Initiative

- Affiliated Professor, 2022–present

National Bureau of Economic Research (NBER)

- Research Associate, Productivity, Innovation, and Entrepreneurship Program, 2013–present

EDUCATION

Graduate School of Arts and Sciences, Columbia University

Ph.D. Economics, with Distinction, 2001.

M.Phil. Economics, 2000.

M.A. Economics, 1998.

Columbia College, Columbia University

B.A. Economics–Political Science, *summa cum laude*, 1996.

TRAINING

Post-Doctoral: Robert Wood Johnson Foundation Scholars in Health Policy Research Program, Department of Health Management and Policy, University of Michigan School of Public Health

HONORS AND AWARDS

- Columbia Yusuf Hamied Faculty Fellowship, 2019
- Robert Wood Johnson Foundation Investigator Award In Health Policy Research, 2007

GRANT SUPPORT

- 2023–2024: National Institute for Health Care Management – Can Improving Pharmaceutical Patent Quality Promote Competition and Reduce Drug Prices? Role: PI.
- 2020–2024: National Science Foundation – The Effects of the World War II Research Effort on Postwar U.S. Science, Technology, and Innovation. Role: co-PI. Subcontract from Duke University (PI: Daniel Gross).
- 2018–2023: European Research Council – Serendipity in Research and Innovation. Role: Subaward PI. Subcontract from the University of Sussex (PI: Ohid Yaqub).
- 2019: Sloan Foundation – Developing and Validating New Measures of Connections Between Science and Patented Technology. Role: PI.
- 2019: Yusuf Hamied Fellowship, Columbia Mailman – Trade Related Intellectual Property Rights: Patents and Drug Prices in India. Role: PI.
- 2017–2019: National Science Foundation – The Effects of Federal Indirect Cost Recovery on Academic Institutions. Role: co-PI (with Pierre Azoulay).
- 2017–2018: National Science Foundation – The Effects of Patents on Innovation, Diffusion, and Access. Role: PI.
- 2013–2015: UK Economic and Social Research Council – TRIPS Implementation and Secondary Pharmaceutical Patenting: An Empirical Analysis. Role: Subaward PI. Subcontract from LSE (PI: Kenneth Shadlen).
- 2014–2015: Marie Curie Action – International Outgoing Fellowships – Serendipity in Science, Technology and Innovation. Role: PI. Subcontract from the University of Sussex.

- 2011–2013: National Science Foundation – Idea and Economic Spillovers from Publicly-funded Biomedical Research. Role: Subaward PI. Subcontract from NBER (PI: Pierre Azoulay).
- 2011–2012: Commonwealth Fund – Analysis of National Datasets on Health Reform Issues. Role: PI.
- 2010–2012: Robert Wood Johnson Foundation – Drug Patent Challenges and Public Health. Role: PI.
- 2009–2010: Commonwealth Fund – Contributing to Health Care Reform: Analysis of National Data Sets. Role: PI.
- 2008–2010: Ford Foundation – TRIPS and Development: The Political Economy of the Patent System. Role: PI.
- 2007–2010: Robert Wood Johnson Foundation – Investigator Award: The Political Economy of the NIH. Role: PI.
- 2005–2007: Merck Foundation – Columbia-Stanford Consortium on Medical Innovation. Role: PI.

ADMINISTRATIVE LEADERSHIP AND ACADEMIC SERVICE

Academic Service

- Member, NIH Council of Councils Working Group on Science of Science (2025–present)
- Committee Member, Congressionally-Mandated NASEM Committee to Evaluate the NASA Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program
- Program committee member, The International Conference on the Science of Science and Innovation (ICSSI), 2023
<https://www.icssi.org/archive2023/speakers2023>
- Judging Panel, UK Office of Health Economics (OHE) 2022 Innovation Policy Prize
<https://www.ohe.org/ohe-prize/2022-question>
- Steering Committee Member, and Co-Director of the Open Data Summer Fellows Program, NBER Innovation Information Initiative (I³) (2018–2026)
<https://iii.pubpub.org/>
- Committee Member, Congressionally-Mandated NASEM Committee to Evaluate Economic and Healthcare Benefits of the NIH Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Program (2020–2021)
<https://nap.nationalacademies.org/read/26376/chapter/1>

Selected University Service

- Senator, Columbia University Senate. (2019–2021)
- Member, Columbia University Senate Committee on External Relations and Research Policy (2019–2021)
- Steering Committee, Columbia University Precision Medicine and Society Initiative (2020–2023)
- Research Director, Department of Health Policy and Management, Columbia University (2016–2021)

Editorial Boards

- Board of Reviewing Editors, *Science* (2025–present)
- Editorial Advisory Board, *Milbank Quarterly* (2021–present)
- Advisory Editor, *Research Policy* (2014–2021)

PUBLICATIONS

Peer reviewed research publications

1. Margaret Kyle, Bhaven N Sampat, and Kenneth C Shadlen. TRIPS, pharmaceutical patents, and generic competition in India. *Health Affairs Scholar*, 4(2), 2025
2. Pierre Azoulay, Matthew Clancy, Danielle Li, and Bhaven N Sampat. What if NIH had been 40% smaller? *Science*, 389(6767):1303–1305, 2025
3. James Archsmith, Anthony Heyes, Matthew Neidell, and Bhaven Sampat. The dynamics of inattention in the (baseball) field. *The Economic Journal*, 2025
4. Daniel P. Gross and Bhaven N. Sampat. The Government Patent Register: A New Resource for Measuring US Government-Funded Patenting. *Research Policy*, 54(1):105142, 2025
5. Lisa Larrimore Ouellette and Bhaven N. Sampat. Using Bayh-Dole Act March-In Rights to Lower US Drug Prices. *JAMA Health Forum*, 5(11):e243775, 2024
6. Daniel P. Gross and Bhaven N. Sampat. America, Jump-Started: World War II R&D and the Takeoff of the U.S. Innovation System. *American Economic Review*, 113(12):3323–3356, 2023
7. Daniel P. Gross and Bhaven N. Sampat. The World War II crisis innovation model: What was it, and where does it apply? *Research Policy*, 52(9):104845, 2023
8. Maya Durvasula, C. Scott Hemphill, Lisa Larrimore Ouellette, Bhaven N. Sampat, and Heidi L Williams. The NBER Orange Book dataset: A user’s guide. *Research Policy*, 52(7):104791, 2023
9. Bhaven N. Sampat. The government and pharmaceutical innovation: Looking back and looking ahead. *Journal of Law, Medicine & Ethics*, 49(1):10–18, 2021

10. Bhaven N. Sampat and Kenneth C. Shadlen. The COVID-19 innovation system. *Health Affairs*, 40(3):400–409, 2021
11. Kevin A. Bryan, Yasin Ozcan, and Bhaven N. Sampat. In-text patent citations: A user’s guide. *Research Policy*, 49(4):103946, May 2020
12. Kenneth C. Shadlen, Bhaven N. Sampat, and Amy Kapczynski. Patents, trade and medicines: Past, present and future. *Review of International Political Economy*, 27(1):75–97, January 2020
13. Bhaven N. Sampat and Heidi L. Williams. How Do Patents Affect Follow-On Innovation? Evidence from the Human Genome. *American Economic Review*, 109(1):203–236, January 2019
14. Pierre Azoulay, Joshua S Graff Zivin, Danielle Li, and Bhaven N. Sampat. Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules. *The Review of Economic Studies*, 86(1):117–152, January 2019
15. Bhaven N. Sampat and Kenneth C. Shadlen. Indian pharmaceutical patent prosecution: The changing role of Section 3(d). *PLOS ONE*, 13(4):e0194714, April 2018
16. Bhaven N. Sampat and Kenneth C. Shadlen. Secondary pharmaceutical patenting: A global perspective. *Research Policy*, 46(3):693–707, April 2017
17. Danielle Li, Pierre Azoulay, and Bhaven N. Sampat. The applied value of public investments in biomedical research. *Science*, 356(6333):78–81, April 2017
18. Bhaven N. Sampat and Kenneth C. Shadlen. Drug patenting in India: looking back and looking forward. *Nature Reviews Drug Discovery*, 14(8):519–520, August 2015
19. Deepak Hegde and Bhaven N. Sampat. Can Private Money Buy Public Science? Disease Group Lobbying and Federal Funding for Biomedical Research. *Management Science*, 61(10):2281–2298, October 2015
20. Bhaven N. Sampat and Kenneth C. Shadlen. TRIPS Implementation and Secondary Pharmaceutical Patenting in Brazil and India. *Studies in Comparative International Development*, 50(2):228–257, June 2015
21. Bhaven N. Sampat and Harold Alan Pincus. Citations in Life Science Patents to Publicly Funded Research at Academic Medical Centers. *Clinical and Translational Science*, 8(6):759–763, December 2015
22. C. Scott Hemphill and Bhaven N. Sampat. Drug Patents at the Supreme Court. *Science*, 339(6126):1386–1387, March 2013
23. Bhaven N. Sampat, Kristin Buterbaugh, and Marcel Perl. New evidence on the allocation of NIH funds across diseases. *The Milbank Quarterly*, 91(1):163–185, 2013
24. Christopher A. Cotropia, Mark A. Lemley, and Bhaven N. Sampat. Do applicant patent citations matter? *Research Policy*, 42(4):844–854, May 2013

25. Bhaven N. Sampat and Tahir Amin. How Do Public Health Safeguards in Indian Patent Law Affect Pharmaceutical Patenting in Practice? *Journal of Health Politics, Policy and Law*, 38(4):735–755, January 2013
26. Arti K Rai and Bhaven N. Sampat. Accountability in patenting of federally funded research. *Nature Biotechnology*, 30(10):953–956, October 2012
27. Amy Kapczynski, Chan Park, and Bhaven N. Sampat. Polymorphs and Prodrugs and Salts (Oh My!): An Empirical Analysis of “Secondary” Pharmaceutical Patents. *PLOS ONE*, 7(12):e49470, December 2012
28. Bhaven N. Sampat. Mission-oriented biomedical research at the NIH. *Research Policy*, 41(10):1729–1741, December 2012
29. Bhaven N. Sampat, Ken Shadlen, and Tahir Amin. Challenges to India’s Pharmaceutical Patent Laws. *Science*, 337(6093):414–415, July 2012
30. C. Scott Hemphill and Bhaven N. Sampat. Evergreening, patent challenges, and effective market life in pharmaceuticals. *Journal of Health Economics*, 31(2):327–339, March 2012
31. Mark A. Lemley and Bhaven N. Sampat. Examiner Characteristics and Patent Office Outcomes. *Review of Economics and Statistics*, 94(3):817–827, August 2012
32. Swathi Padmanabhan, Tahir Amin, Bhaven N. Sampat, Robert Cook-Deegan, and Subhashini Chandrasekharan. Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India. *Nature Biotechnology*, 30(2):193–193, February 2012
33. C. Scott Hemphill and Bhaven N. Sampat. When Do Generics Challenge Drug Patents?: When Do Generics Challenge Drug Patents? *Journal of Empirical Legal Studies*, 8(4):613–649, December 2011
34. Peter Muennig, Bhaven N. Sampat, Nicholas Tilipman, Lawrence D. Brown, and Sherry A. Glied. We All Want It, but We Don’t Know What It Is: Toward a Standard of Affordability for Health Insurance Premiums. *Journal of Health Politics, Policy and Law*, 36(5):829–853, October 2011
35. Bhaven N. Sampat and Michael Drummond. Another special relationship? Interactions between health technology policies and health care systems in the United States and the United Kingdom. *Journal of Health Politics, Policy and Law*, 36(1):119–139, February 2011
36. Bhaven N. Sampat and Frank R. Lichtenberg. What are the respective roles of the public and private sectors in pharmaceutical innovation? *Health Affairs (Project Hope)*, 30(2):332–339, February 2011
37. Bhaven N. Sampat. When Do Applicants Search for Prior Art? *The Journal of Law and Economics*, 53(2):399–416, May 2010
38. Julia Carbone, E Richard Gold, Bhaven N. Sampat, Subhashini Chandrasekharan, Lori Knowles, Misha Angrist, and Robert Cook-Deegan. DNA patents and diagnostics: not a pretty picture. *Nature Biotechnology*, 28(8):784–791, August 2010

39. Deepak Hegde and Bhaven N. Sampat. Examiner citations, applicant citations, and the private value of patents. *Economics Letters*, 105(3):287–289, December 2009
40. Bhaven N. Sampat. Academic Patents and Access to Medicines in Developing Countries. *American Journal of Public Health*, 99(1):9–17, January 2009
41. Juan Alcácer, Michelle Gittelman, and Bhaven N. Sampat. Applicant and examiner citations in U.S. patents: An overview and analysis. *Research Policy*, 38(2):415–427, March 2009
42. Anthony D. So, Bhaven N. Sampat, Arti K Rai, Robert Cook-Deegan, Jerome H Reichman, Robert Weissman, and Amy Kapczynski. Is Bayh-Dole Good for Developing Countries? Lessons from the US Experience. *PLoS Biology*, 6(10):e262, October 2008
43. Mark J. Russo, Annetine C. Gelijns, Lynne W. Stevenson, Bhaven N. Sampat, Keith D. Aaronson, Dale G. Renlund, Deborah D. Ascheim, Kimberly N. Hong, Mehmet C. Oz, Alan J. Moskowitz, Eric A. Rose, and Leslie W. Miller. The Cost of Medical Management in Advanced Heart Failure During the Final Two Years of Life. *Journal of Cardiac Failure*, 14(8):651–658, October 2008
44. Pierre Azoulay, Ryan Michigan, and Bhaven N. Sampat. The Anatomy of Medical School Patenting. *New England Journal of Medicine*, 357(20):2049–2056, November 2007
45. Bhaven N. Sampat. Patenting and US academic research in the 20th century: The world before and after Bayh-Dole. *Research Policy*, 35(6):772–789, July 2006
46. David C. Mowery and Bhaven N. Sampat. The Bayh-Dole Act of 1980 and University–Industry Technology Transfer: A Model for Other OECD Governments? *The Journal of Technology Transfer*, 30(1):115–127, December 2004
47. R. R Nelson, A. Peterhansl, and Bhaven N. Sampat. Why and how innovations get adopted: A tale of four models. *Industrial and Corporate Change*, 13(5):679–699, October 2004
48. Bhaven N. Sampat, David C. Mowery, and Arvids A. Ziedonis. Changes in university patent quality after the Bayh–Dole act: A re-examination. *International Journal of Industrial Organization*, 21(9):1371–1390, November 2003
49. David C. Mowery, Bhaven N. Sampat, and Arvids A. Ziedonis. Learning to Patent: Institutional Experience, Learning, and the Characteristics of U.S. University Patents After the Bayh-Dole Act, 1981-1992. *Management Science*, 48(1):73–89, January 2002
50. Jeannette Colyvas, Michael Crow, Annetine Gelijns, Roberto Mazzoleni, Richard R. Nelson, Nathan Rosenberg, and Bhaven N. Sampat. How Do University Inventions Get Into Practice? *Management Science*, 48(1):61–72, January 2002
51. David C. Mowery and Bhaven N. Sampat. University Patents and Patent Policy Debates in the USA, 1925-1980. *Industrial and Corporate Change*, 10(3):781–814, August 2001
52. David C Mowery, Richard R Nelson, Bhaven N. Sampat, and Arvids A Ziedonis. The growth of patenting and licensing by U.S. universities: An assessment of the effects of the Bayh–Dole act of 1980. *Research Policy*, 30(1):99–119, January 2001

53. Richard R. Nelson and Bhaven N. Sampat. Making sense of institutions as a factor shaping economic performance. *Journal of Economic Behavior & Organization*, 44(1):31–54, January 2001
54. David C. Mowery and Bhaven N. Sampat. Patenting and Licensing University Inventions: Lessons from the History of the Research Corporation. *Industrial and Corporate Change*, 10(2):317–355, June 2001

Book

1. David C. Mowery, Richard R. Nelson, Bhaven N. Sampat, and Arvids A. Ziedonis. *Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act*. Stanford University Press, 2004

Book chapters, law reviews, editorials, and other publications

1. Pierre Azoulay, Daniel P Gross, and Bhaven N Sampat. Indirect cost recovery in US innovation policy: History, evidence, and avenues for reform. *NBER Entrepreneurship and Innovation Policy and the Economy*, 5, 2025
2. C. Scott Hemphill and Bhaven N. Sampat. Patents, Innovation, and Competition in Pharmaceuticals: The Hatch-Waxman Act After 40 Years. *Journal of Economic Perspectives*, 39(2):1–26, 2025
3. Daniel P. Gross and Bhaven N. Sampat. New Data, Old Debates: US Government-Funded R&D and Patent Policy, February 2025. Centre for Economic Policy Research, VoxEU column
4. Bhaven N. Sampat. Doubling down: Will large increases in the NIH budget promote more meaningful medical innovation? *Journal of Law, Medicine & Ethics*, 51(S2):21–23, 2023
5. Bhaven N. Sampat. The History and Political Economy of NIH Peer Review. *Brookings/IFP Building a Better NIH Series*, 2023
6. C. Scott Hemphill and Bhaven N. Sampat. Fixing the FDA's orange book. *Health Affairs*, pages 10–1377, 2022
7. Daniel P. Gross and Bhaven N. Sampat. Crisis innovation: Historical evidence, insights, and open questions. *NBER Reporter*, (3):12–15, 2022
8. Lisa Larrimore Ouellette, Michael Abramowicz, Daniel Hemel, and Bhaven N. Sampat. What role should governments play in setting rewards for medical innovation? *NYU Journal of Intellectual Property & Entertainment Law*, 11, 2021
9. Daniel P. Gross and Bhaven N. Sampat. Crisis Innovation Policy from World War II to COVID-19. *NBER Entrepreneurship and Innovation Policy and the Economy*, 1:135–181, 2021
10. Robert Cook-Deegan and Bhaven N. Sampat. An ARPA for Health Research? *Milbank Quarterly (Opinion)*, 2021
11. Daniel Gross and Bhaven N. Sampat. The Economics of Crisis Innovation Policy: A Historical Perspective. *American Economic Review Papers and Proceedings*, 2021

12. Bhaven N. Sampat. Whose Drugs Are These? *Issues in Science and Technology*, 2020
13. Bhaven N. Sampat. Comment on “Leveraging public research for innovation and growth – a conceptual framework and common metrics”. In Suma Athreye Anthony Arundel and Sacha Wunch-Vincent, editors, *Harnessing Public Research for Innovation in the 21st Century: An International Assessment of Knowledge Transfer Policies*. Cambridge University Press, 2020
14. Bhaven N. Sampat. Comment on “Local effects of land grant colleges on agricultural innovation and output”. In *Economics of Research and Innovation in Agriculture*. University of Chicago Press, 2020
15. Amy Kapczynski, Bhaven N. Sampat, and Kenneth C Shadlen. The TPP and drug prices. *Foreign Affairs*, 2016
16. Arti Rai and Bhaven N. Sampat. Accountability, Government Rights, and the Public Interest: A Thirty-Year Retrospective. In Donald Siegel Albert Link and Mike Wright, editors, *The Chicago Handbook of University Technology Transfer and Academic Entrepreneurship*. University of Chicago Press, 2014
17. Arti K. Rai, John R. Allison, and Bhaven N. Sampat. University Software Ownership and Litigation. In Michael Abramowicz, James E. Daily, and F. Scott Kieff, editors, *Perspectives on Patentable Subject Matter*, pages 336–375. Cambridge University Press, New York, 2014
18. Bhaven N. Sampat. Review of “prevention vs. treatment: What’s the right balance?”. *Global Public Health*, 8(2):236–239, February 2013
19. Pierre Azoulay, Joshua S. Graff Zivin, and Bhaven N. Sampat. The Diffusion of Scientific Knowledge across Time and Space: Evidence from Professional Transitions for the Superstars of Medicine. In Josh Lerner and Scott Stern, editors, *The Rate and Direction of Inventive Activity Revisited*. University of Chicago Press, 2012
20. Bhaven N. Sampat. Lessons from Bayh–Dole. *Nature*, 468(7325):755–756, December 2010
21. Bhaven N. Sampat. Research Locally, Diffuse Globally? American Universities, Patents and Global Public Health. *Columbia Journal of International Affairs*, November 2010
22. Bhaven N. Sampat. Catching Up In Indian Pharmaceuticals and Software: The Roles That Patents Did and Did Not Play. In H. Odagiri, A. Goto, A. Sunami, and R.R. Nelson, editors, *Intellectual Property Rights, Development, and Catch-Up*. Oxford University Press, April 2010
23. Bhaven N. Sampat. The Dismal Science, the Crown Jewel and the Endless Frontier. In D. Foray, editor, *The New Economics of Technology Policy*. Edward Elgar Publishing, 2009
24. Arti Rai, John Allison, Bhaven N. Sampat, and Colin Crossman. University Software Ownership and Litigation: A First Examination. *North Carolina Law Review*, 87:1519–1570, January 2009
25. Mark A. Lemley and Bhaven N. Sampat. Is the Patent Office a Rubber Stamp? *Emory Law Journal*, 58:181, 2008

26. Bhaven N. Sampat. University Patenting: Shaping a New Government Patent Policy. In D. Guston and D. Sarewitz, editors, *Shaping Science and Technology Policy: The Next Generation of Research*. University of Wisconsin Press, Madison, 2007
27. Bhaven N. Sampat, David Mowery, and Arvids Ziedonis. Changes in University Patent Quality After Bayh–Dole: A Re–Examination. In Donald S. Siegel, editor, *Technological Entrepreneurship: The International Library of Entrepreneurship Series*. Edward Elgar, Northampton, 2007
28. David C. Mowery and Bhaven N. Sampat. The Bayh-Dole Act of 1980 and University-Industry Technology Transfer. In Dominique Foray and Brian Kahin, editors, *Advancing Knowledge and The Knowledge Economy*. MIT Press, Cambridge, 2006
29. David C. Mowery and Bhaven N. Sampat. Universities in National Innovation Systems. In Jan Fagerberg and David C. Mowery, editors, *The Oxford Handbook of Innovation*. Oxford University Press, 2006. 10.1093/oxfordhb/9780199286805.003.0008
30. Mark Lemley, Doug Lichtman, and Bhaven N. Sampat. What to do about bad patents? *Regulation*, 2005
31. Bhaven N. Sampat and Arvids A. Ziedonis. Patent Citations and the Economic Value of Patents. In Henk F. Moed, Wolfgang Glänzel, and Ulrich Schmoch, editors, *Handbook of Quantitative Science and Technology Research: The Use of Publication and Patent Statistics in Studies of S&T Systems*, pages 277–298. Springer Netherlands, Dordrecht, 2005
32. Richard Nelson and Bhaven N. Sampat. Making Sense of Institutions as a Factor Shaping Economic Performance. In Geoffrey Hodgson, editor, *Recent Developments in Institutional Economics*, Critical Studies in Economic Institutions. Edward Elgar, 2003
33. Bhaven N. Sampat and Richard R. Nelson. The evolution of university patenting and licensing procedures: An empirical study of institutional change. In Paul Ingram and Brian S. Silverman, editors, *The New Institutionalism in Strategic Management*, volume 19 of *Advances in Strategic Management*, pages 135–164. Emerald Group Publishing Limited, January 2000
34. David Mowery, Richard Nelson, Bhaven N. Sampat, and Arvids Ziedonis. The effects of the Bayh-Dole Act on US university research and technology transfer. In Fumio Kodama Lewis Branscomb and Richard Florida, editors, *Industrializing Knowledge*. MIT Press, 1999

Other: Policy Reports and Government Submissions

1. Pierre Azoulay, Daniel P. Gross, Lisa Larrimore Ouellette, and Bhaven N. Sampat. Brief of Scholars of Economics and Innovation as Amici Curiae in Support of Plaintiffs-Appellees, June 2025. *Massachusetts v. NIH*, No. 25-1343, 25-1344, & 25-1345 in the 1st Cir. (Jun. 20, 2025)
2. Maya M. Durvasula, Lisa Larrimore Ouellette, and Bhaven N. Sampat. Response to Request for Information on Draft NIH Intramural Research Program Policy: Promoting Equity Through Access Planning, July 2024. Submitted July 22, 2024
3. Lisa Larrimore Ouellette and Bhaven N. Sampat. Response to Request for Information Regarding the Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights, February 2024. Submitted February 6, 2024

4. Bhaven N. Sampat. *Global Innovation Report*, chapter The Economics of Health Innovation: Looking Back and Looking Forward. World Intellectual Property Organization, 2019
5. Bhaven N. Sampat. Science policy research report: The effects of patents on innovation (reprinted as NBER working paper 2018). Technical report, National Science Foundation, 2018
6. Bhaven N. Sampat. Intellectual property rights and pharmaceuticals: The case of antibiotics. Technical report, World Intellectual Property Organization Economic Research Working Paper 26, 2015
7. Bhaven N. Sampat. The impact of publicly funded biomedical and health research: A review. Technical report, Appendix D of “Measuring the Impact of Federal Investments in Research: A Workshop Summary” (National Academies Press), 2011
8. Bhaven N. Sampat. The Bayh-Dole model in developing countries: Reflections on the Indian bill on publicly funded intellectual property. Technical report, UNCTAD-ICTSD Project on Intellectual Property Rights and Sustainable Development, 2009

SELECTED WORK IN PROGRESS

- The Therapeutic Consequences of the War: World War II Medical Research and the Mid-Century Expansion of Biomedicine (with Daniel Gross), NBER Working Paper 33457
- Retreating from Science: The Long-Run Effects of the 1970s U.S. Military Disinvestment from Research (with Daniel P. Gross and Hansen Zhang)
- Taking Stock: The Past and Future of Biomedical Research Policy (under preparation for NBER Science of Science Funding *Taking Stock* volume)
- The Organizational Structure of the NIH (with Daniel Gross and Jinkang Huo)
- *The Crown Jewel: The NIH and Biomedical Research Policy, 1945-2020*

INVITED TALKS AND PRESENTATIONS (SINCE 2024)

- Panelist, “A New Academic Social Contract,” American Enterprise Institute, May 2026.
- “The Social Contract for Science and the NIH,” Charm City Colloquium on Law and Bioethics, April 2026.
- Panelist, “The Telephone at 150,” Charles River Museum of Science and Industry, April 2026.
- “The Past and Future of Biomedical Research Funding,” University of Illinois Law and Economics Workshop, April 2026.
- “The Therapeutic Consequences of the War: World War II and the 20th Century Expansion of Biomedicine,” University of Illinois Economics of Science and IP Conference, April 2026.
- “The Therapeutic Consequences of the War: World War II and the 20th Century Expansion of Biomedicine,” Kellogg Strategy Seminar, April 2026.

- Panelist, “The Future of Research and Higher Education in a Shifting Policy Landscape,” Allied Social Science Association Annual Meetings, January 2026.
- Panelist, “Bayh-Dole March-in Rights,” American Bar Association Public Contract Committee Seminar, December 2025.
- “The History of Federal Science Policy,” American Historical Association Congressional Briefing, December 2025.
- Panelist, “Rethinking America’s Social Compact with Science,” Consortium for Science Policy and Outcomes, November 2025.
- Guest Lecture, “The US Patent System and Innovation Policy,” MIT Sloan Economics of Ideas, Innovation, and Entrepreneurship, November 2025.
- “The Past and Future of Biomedical Research Funding,” NBER Economics of Science Conference, September 2025.
- Keynote, “Public Funding, Patents, and Pharmaceuticals,” Intellectual Property Rights, Science, and Innovation: Implications for Drug Discovery and the Health Sector, Università Cattolica del Sacro Cuore, Milano, September 2025.
- Keynote, “War, Crisis, and Innovation Policy,” European Policy for Intellectual Property Conference, University of Antwerp, September 2025.
- Panelist, “The Structure of Public Funding for Academic Science,” NBER Summer Institute Science of Science Funding Meeting, July 2025.
- “The Therapeutic Consequences of the War: World War II and the 20th Century Expansion of Biomedicine,” NBER Summer Institute Innovation Meeting, July 2025.
- “Rethinking the NIH: Indirect Cost Recovery Policy,” Arizona State University Consortium for Science, Policy, and Outcomes, May 2025.
- Panelist, “The Impact of Research Security Policies and Requirements on the Research Ecosystem,” Committee on Assessing Research Security Efforts in Higher Education, National Academies of Sciences, Engineering, and Medicine, May 2025.
- “Indirect Cost Recovery in U.S. Innovation Policy,” NBER Entrepreneurship and Innovation Policy and the Economy Meetings, April 2025.
- Government Challenges to U.S. Patent Rights Conference, Banbury Center, Cold Spring Harbor Laboratory, March 2025.
- “Science Policy, War, and Peace,” Science Policy and Diplomacy Distinguished Speaker Series, University of Arizona, October 2024.
- Panelist, American University Law Review Federal Circuit Symposium, Washington College of Law — American University, October 2024.
- “Hatch-Waxman at 40,” Law and Economics Seminar, University of Pennsylvania Law School, October 2024.
- Conference on Patent Anti-Evergreening: Policies and Experiences from an International Perspective, Washington College of Law — American University, September 2024.

- “U.S. Science and Technology Policy: Solving for What and for Whom,” Science and Technology Policy Fellows Training Session, American Association for the Advancement of Science (AAAS), September 2024.
- “Hatch-Waxman at 40,” Health Care at Reasonable Cost: The Hatch-Waxman Act at 40 and Beyond, NYU Law School, September 2024.
- “Hatch-Waxman at 40,” Brookings Institution, September 2024.
- Discussant, “Institutional Concentration of Elite Researchers,” Science of Science Funding, NBER Summer Institute, July 2024.
- “The Feasibility of Using Bayh-Dole March-In Rights to Lower U.S. Drug Prices,” Life Sciences Symposium, Bates White Economic Consulting, May 2024.
- “The Therapeutic Consequences of the War: World War II Medical Research and the Mid-Century Expansion of Biomedicine,” Shidler College of Business Speaker Series, University of Hawaii at Manoa, March 2024.
- “Evaluating Benefits from Publicly Funded Research Using Patent-Data: Applications, Benefits, & Misuse,” American Evaluation Association, March 2024.
- “U.S. Science and Technology Policy: World War II to Covid-19,” Science and Technology Policy Fellows Training Session, American Association for the Advancement of Science (AAAS), February 2024.
- Panelist, “How Can Taxpayer-Funded Science Yield Drugs That Are Innovative and Affordable?,” Issues in Science and Technology, January 2024.

CONFERENCES AND PANELS ORGANIZED

1. “Valuing the Medical Innovation System” National Bureau of Economic Research, March 2026
2. “The International Conference on the Science of Science and Innovation” Boulder, Colorado, July 2026
3. “The International Conference on the Science of Science and Innovation” National Academies of Sciences, Engineering and Medicine, July 2024
4. “Workshop on empirical research on Pharmaceutical IP” (Columbia University, HEC Lausanne, HEC Paris) February 2021.
5. “The Past and Future of Innovation Policy: The Bush Report at 75 Years” Super-session panel at Association for Public Policy Analysis and Management (APPAM) Annual Conference, November 2020
6. “Secondary Pharmaceutical Patents” conference, NYU Law School, February 2016
7. “TRIPS@10” conference on the impact of the Trade Related Intellectual Property Rights Agreement, Columbia Earth Institute, November 2005

TEACHING

- War, Crisis, and Innovation – ASU, Undergraduate and Masters, Spring 2025
- Economics of Science and Technology Policy — ASU, PhD, Fall 2024
- Economics of Biomedical Innovation — Columbia, MPH/MHA, Spring 2023; Fall 2021; Spring 2021; Fall 2019; Spring 2019
- Innovation in Health Policy — Columbia, MPH, Spring 2020
- Economics of Precision Medicine — Columbia, MPH/MHA, Spring 2020
- Vaccine Innovation and Public Policy — Columbia, MPH/MHA, Fall 2020
- Evidence, Politics, Health Policy (with Ronald Bayer) — Columbia, MPH, Spring 2018
- Economics of Innovation — ASU, PhD, Spring 2018
- Economics of Medical Technology — Columbia, MPH/MHA, Fall 2017; Fall 2016; Spring 2015; Fall 2013
- Program Evaluation — Columbia, MPH, Spring 2017; Spring 2008; Spring 2007
- Integration of Science and Practice — Columbia, MPH, Fall 2016; Spring 2014; Fall 2013; Spring 2013; Fall 2012
- Research Methods 1 — Columbia, MPH, Spring 2015; Spring 2014; Spring 2013
- Health and Development — Columbia, MPH/MPP, Spring 2012; Spring 2011; Spring 2010
- Economic Evaluation of Health Technologies — Columbia, MPH/MHA, Spring 2012; Spring 2008
- Analytic Methods for Health Service Management — Columbia, MHA, Spring 2009
- Economics and Ethics of New Technologies — Rockefeller University, PhD, Fall 2009
- Science, Technology and Sustainable Development — Columbia, Sustainable Development PhD Seminar, Spring 2008
- U.S. Science and Technology Policy — Columbia, MPA, Spring 2007; Spring 2006